JP2009511892A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009511892A5 JP2009511892A5 JP2008535094A JP2008535094A JP2009511892A5 JP 2009511892 A5 JP2009511892 A5 JP 2009511892A5 JP 2008535094 A JP2008535094 A JP 2008535094A JP 2008535094 A JP2008535094 A JP 2008535094A JP 2009511892 A5 JP2009511892 A5 JP 2009511892A5
- Authority
- JP
- Japan
- Prior art keywords
- variable domain
- chain variable
- antibody
- heavy chain
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims 68
- 239000003446 ligand Substances 0.000 claims 67
- 229920001184 polypeptide Polymers 0.000 claims 45
- 108090000765 processed proteins & peptides Proteins 0.000 claims 45
- 102000004196 processed proteins & peptides Human genes 0.000 claims 45
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims 15
- 239000012634 fragment Substances 0.000 claims 15
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 13
- 239000004471 Glycine Substances 0.000 claims 12
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 12
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 claims 12
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims 11
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 claims 10
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 9
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 9
- 108090000623 proteins and genes Proteins 0.000 claims 7
- 210000004602 germ cell Anatomy 0.000 claims 6
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims 5
- 241000282412 Homo Species 0.000 claims 4
- 210000003719 b-lymphocyte Anatomy 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 4
- 108010047303 von Willebrand Factor Proteins 0.000 claims 4
- 102100036537 von Willebrand factor Human genes 0.000 claims 4
- 229960001134 von willebrand factor Drugs 0.000 claims 4
- 108010088751 Albumins Proteins 0.000 claims 3
- 102000009027 Albumins Human genes 0.000 claims 3
- 239000004475 Arginine Chemical group 0.000 claims 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Chemical group OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 3
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- RTQWWZBSTRGEAV-PKHIMPSTSA-N 2-[[(2s)-2-[bis(carboxymethyl)amino]-3-[4-(methylcarbamoylamino)phenyl]propyl]-[2-[bis(carboxymethyl)amino]propyl]amino]acetic acid Chemical compound CNC(=O)NC1=CC=C(C[C@@H](CN(CC(C)N(CC(O)=O)CC(O)=O)CC(O)=O)N(CC(O)=O)CC(O)=O)C=C1 RTQWWZBSTRGEAV-PKHIMPSTSA-N 0.000 claims 2
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims 2
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims 2
- 101000600756 Homo sapiens 3-phosphoinositide-dependent protein kinase 1 Proteins 0.000 claims 2
- 101000577881 Homo sapiens Macrophage metalloelastase Proteins 0.000 claims 2
- 101001117146 Homo sapiens [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial Proteins 0.000 claims 2
- -1 IgE Proteins 0.000 claims 2
- 102000008070 Interferon-gamma Human genes 0.000 claims 2
- 108010074328 Interferon-gamma Proteins 0.000 claims 2
- 102100027998 Macrophage metalloelastase Human genes 0.000 claims 2
- 241001465754 Metazoa Species 0.000 claims 2
- 101100370002 Mus musculus Tnfsf14 gene Proteins 0.000 claims 2
- 108010071390 Serum Albumin Proteins 0.000 claims 2
- 102000007562 Serum Albumin Human genes 0.000 claims 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 2
- 102100024148 [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial Human genes 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 229940120638 avastin Drugs 0.000 claims 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 2
- 229940082789 erbitux Drugs 0.000 claims 2
- 229960003297 gemtuzumab ozogamicin Drugs 0.000 claims 2
- 229940048921 humira Drugs 0.000 claims 2
- 229960001001 ibritumomab tiuxetan Drugs 0.000 claims 2
- 229960003130 interferon gamma Drugs 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 2
- 229940116176 remicade Drugs 0.000 claims 2
- 229940115586 simulect Drugs 0.000 claims 2
- 241000894007 species Species 0.000 claims 2
- 229960005267 tositumomab Drugs 0.000 claims 2
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims 1
- 241001529936 Murinae Species 0.000 claims 1
- 102000007079 Peptide Fragments Human genes 0.000 claims 1
- 108010033276 Peptide Fragments Proteins 0.000 claims 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 1
- 102000004338 Transferrin Human genes 0.000 claims 1
- 108090000901 Transferrin Proteins 0.000 claims 1
- 102000007238 Transferrin Receptors Human genes 0.000 claims 1
- 108010033576 Transferrin Receptors Proteins 0.000 claims 1
- 229940112129 campath Drugs 0.000 claims 1
- 229940022353 herceptin Drugs 0.000 claims 1
- 108010068617 neonatal Fc receptor Proteins 0.000 claims 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 claims 1
- 238000002823 phage display Methods 0.000 claims 1
- 229940107685 reopro Drugs 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 229940036185 synagis Drugs 0.000 claims 1
- 239000012581 transferrin Substances 0.000 claims 1
- 241001515965 unidentified phage Species 0.000 claims 1
- 229940099073 xolair Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0520644A GB0520644D0 (en) | 2005-10-11 | 2005-10-11 | Antibody polypeptide library screening and selected antibody polypeptides |
| GB0521140A GB0521140D0 (en) | 2005-10-18 | 2005-10-18 | Antibody polypeptide library screening and selected antibody polypeptides |
| PCT/GB2006/003781 WO2007042809A2 (en) | 2005-10-11 | 2006-10-11 | Antibody polypeptide library screening and selected antibody polypeptides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009511892A JP2009511892A (ja) | 2009-03-19 |
| JP2009511892A5 true JP2009511892A5 (https=) | 2009-10-22 |
Family
ID=37943170
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008535094A Pending JP2009511892A (ja) | 2005-10-11 | 2006-10-11 | 抗体ポリペプチドライブラリーのスクリーニングと選択された抗体ポリペプチド |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20100168393A1 (https=) |
| EP (1) | EP1951754A2 (https=) |
| JP (1) | JP2009511892A (https=) |
| AU (1) | AU2006300951A1 (https=) |
| CA (1) | CA2625222A1 (https=) |
| WO (1) | WO2007042809A2 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2390425T3 (es) | 2000-12-22 | 2012-11-12 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Uso de moléculas de orientación repulsivas (RGM) y sus moduladores |
| CN101277974A (zh) | 2005-09-30 | 2008-10-01 | 阿伯特有限及两合公司 | 排斥性引导分子(rgm)蛋白质家族的蛋白质的结合结构域及其功能性片段和它们的用途 |
| US8962803B2 (en) | 2008-02-29 | 2015-02-24 | AbbVie Deutschland GmbH & Co. KG | Antibodies against the RGM A protein and uses thereof |
| CN104004094B (zh) * | 2008-06-25 | 2017-09-22 | 艾斯巴技术-诺华有限责任公司 | 使用通用抗体构架进行的兔抗体的人源化 |
| MX345039B (es) | 2008-06-25 | 2017-01-16 | Esbatech Alcon Biomed Res Unit | Anticuerpos estables y solubles que inhiben el tnfa. |
| AU2020201002B2 (en) * | 2008-06-25 | 2022-04-07 | Novartis Ag | Humanization of rabbit antibodies using a universal antibody framework |
| CN102656190A (zh) | 2009-12-08 | 2012-09-05 | 雅培股份有限两合公司 | 用于在视网膜神经纤维层变性治疗中使用的针对rgm a蛋白质的单克隆抗体 |
| US8883985B2 (en) | 2010-02-16 | 2014-11-11 | National University Corporation Kyoto Institute Of Technology | Antibody-immobilized carrier, method of producing antibody-immobilized carrier, and use of said antibody-immobilized carrier |
| PL2606064T3 (pl) * | 2010-08-16 | 2015-07-31 | Novimmune Sa | Sposoby wytwarzania wieloswoistych i wielowartościowych przeciwciał |
| AR083495A1 (es) | 2010-10-22 | 2013-02-27 | Esbatech Alcon Biomed Res Unit | Anticuerpos estables y solubles |
| WO2012105833A1 (en) * | 2011-02-01 | 2012-08-09 | Bac Ip B.V. | Antigen-binding protein directed against epitope in the ch1 domain of human igg antibodies |
| NZ714482A (en) | 2012-01-27 | 2017-08-25 | Abbvie Inc | Composition and method for diagnosis and treatment of diseases associated with neurite degeneration |
| CN107814845B (zh) * | 2016-09-14 | 2021-02-09 | 浙江特瑞思药业股份有限公司 | 新的抗pd-1纳米抗体及其应用 |
| CN107857816B (zh) * | 2017-10-17 | 2020-11-06 | 北京大学 | 一种抗干扰素α-2b纳米抗体及其应用 |
| EP3737692A4 (en) | 2018-01-09 | 2021-09-29 | Elstar Therapeutics, Inc. | CALRETICULIN AND MODIFIED T-LYMPHOCYTES BINDING CONSTRUCTIONS FOR THE TREATMENT OF DISEASES |
| US12152073B2 (en) | 2018-03-14 | 2024-11-26 | Marengo Therapeutics, Inc. | Multifunctional molecules that bind to calreticulin and uses thereof |
| EP3818083A2 (en) | 2018-07-03 | 2021-05-12 | Elstar Therapeutics, Inc. | Anti-tcr antibody molecules and uses thereof |
| GB2595980B (en) * | 2019-01-04 | 2023-06-14 | Marengo Therapeutics Inc | Anti-TCR antibody molecules and uses thereof |
| JP7710373B2 (ja) | 2019-02-21 | 2025-07-18 | マレンゴ・セラピューティクス,インコーポレーテッド | T細胞関連のがん細胞に結合する多機能性分子およびその使用 |
| AU2020224681A1 (en) | 2019-02-21 | 2021-09-16 | Marengo Therapeutics, Inc. | Antibody molecules that bind to NKp30 and uses thereof |
| CN116234829A (zh) | 2020-01-03 | 2023-06-06 | 马伦戈治疗公司 | 抗tcr抗体分子及其用途 |
| EP4341298A4 (en) * | 2021-06-22 | 2025-04-16 | University of Virginia Patent Foundation | COMPOSITIONS AND METHODS FOR DETECTING AND REGULATING FIBRONECTIN-INTEGRIN INTERACTIONS AND SIGNALING |
| CN114195891B (zh) * | 2021-12-22 | 2023-05-12 | 北京世纪沃德生物科技有限公司 | 一种crp驼源单域抗体及其制备方法和应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2136092T3 (es) * | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| GB9722131D0 (en) * | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| ZA9811162B (en) * | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
| US20060252028A1 (en) * | 2002-08-16 | 2006-11-09 | Hiroshi Ueda | Method of assaying interaction between proteins |
| WO2004065611A1 (ja) * | 2003-01-21 | 2004-08-05 | Chugai Seiyaku Kabushiki Kaisha | 抗体の軽鎖スクリーニング方法 |
| EP1711527A4 (en) * | 2003-12-15 | 2008-09-03 | Dendreon Corp | HLA-DR SPECIFIC ANTIBODIES, COMPOSITIONS AND METHODS |
-
2006
- 2006-10-11 WO PCT/GB2006/003781 patent/WO2007042809A2/en not_active Ceased
- 2006-10-11 US US12/083,368 patent/US20100168393A1/en not_active Abandoned
- 2006-10-11 CA CA002625222A patent/CA2625222A1/en not_active Abandoned
- 2006-10-11 EP EP06794731A patent/EP1951754A2/en not_active Withdrawn
- 2006-10-11 AU AU2006300951A patent/AU2006300951A1/en not_active Abandoned
- 2006-10-11 JP JP2008535094A patent/JP2009511892A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009511892A5 (https=) | ||
| JP7676474B2 (ja) | Cd47およびpd-l1に特異的な抗体 | |
| US10358493B2 (en) | Bispecific format suitable for use in high-through-put screening | |
| US10677787B2 (en) | Antibody screening methods | |
| Peng et al. | Mining naive rabbit antibody repertoires by phage display for monoclonal antibodies of therapeutic utility | |
| US12247075B2 (en) | BTN3A binding proteins and uses thereof | |
| US11332522B2 (en) | Modified variable domain molecules and methods for producing them | |
| US20160145328A1 (en) | Modified Variable Domain Molecules And Methods For Producing And Using Same | |
| CN107955071A (zh) | 人源抗人cd47抗体及其编码基因与应用 | |
| JP2009511892A (ja) | 抗体ポリペプチドライブラリーのスクリーニングと選択された抗体ポリペプチド | |
| WO2018050027A1 (zh) | 一种能够特异性地结合pd-1的抗体及其功能片段 | |
| US20080003617A1 (en) | Methods for the identification and the isolation of epitope specific antibodies | |
| Sandeep et al. | Engineered polyspecific antibodies: A new frontier in the field of immunotherapeutics | |
| JP2009508521A5 (https=) | ||
| JP6918399B2 (ja) | 抗体ナイーブライブラリーを生成する方法、前記ライブラリー及びその用途 | |
| US20170306039A1 (en) | Human vh domain scaffolds | |
| JP2012232948A5 (https=) | ||
| WO2022037527A1 (zh) | 结合bcma的单可变结构域及抗原结合分子 | |
| Lai et al. | Synthetic Antibody Engineering: Concepts and Applications |